Elacestrant (ELA) vs Standard of Care (SOC) in ER+/HER2-- Advanced (adv) or Metastatic Breast Cancer (mBC) With ESR1 Mutation (ESR1-mut): Key Biomarkers and Clinical Subgroup Analyses From the Phase 3 EMERALD Trial.
Autor: | Bardia, Aditya, O'Shaughnessy, Joyce, Bidard, Francois-Clement, Aftimos, Phillipe, Cortes, Javier, Lu, Janice, Tonini, Giulia, Thea, Kathy Puyana, Paoli, Alessandro, Kaklamani, Virginia |
---|---|
Předmět: | |
Zdroj: | Journal of Oncology Navigation & Survivorship; Oct2024, Vol. 15 Issue 10, p310-311, 2p |
Databáze: | Complementary Index |
Externí odkaz: |